Although Pola‐BR represents a novel, effective therapeutic regimen for patients with transplantation‐ineligible R/R DLBCL, many patients are either transplant‐eligible or may require CAR‐T cell therapy in the future. The gene discussed is POLA1; the disease is diffuse large B-cell lymphoma.